Irodalom:
1. Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, DiSanti W, Chun A, Keenan G,
Mamun K: A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn’s
disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving
intravenous hydrocortisone. J Clin Gastroenterol 2007;41:677-681.
2. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D,
Li J, Kent JD, Pollack PF: Adalimumab for maintenance of clinical response and remission in patients
with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52-65.
3. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D,
Kent JD, Bittle B, Li J, Pollack PF: Adalimumab for maintenance treatment of Crohn’s disease: results
of the CLASSIC II trial. Gut 2007;56:1232-1239.
4. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D’Haens G, Li J, Rosenfeld
MR, Kent JD, Pollack PF: Adalimumab induction therapy for Crohn disease previously treated with
infliximab: a randomized trial. Ann Intern Med 2007;146:829-838.
5. Kaplan GG, Hur C, Korzenik J, Sands BE: Infliximab dose escalation vs. initiation of adalimumab for
loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26:
1509-1520.
6. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts
P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S: American gastroenterological
association consensus development conference on the use of biologics in the treatment of inflammatory
bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-339.
7. Veres G, Baldassano RN, Mamula P: Infliximab therapy for pediatric Crohn’s disease. Expert Opin Biol
Ther 2007;7:1869-1880.
8. Afzal NA, Ozzard A, Keady S, Thomson M, Murch S, Heuschkel R: Infliximab delays but does not avoid
the need for surgery in treatment-resistant pediatric Crohn’ disease. Dig Dis Sci 2007;52:3329-3333.
9. Carbone J, Gonzalez-Lara V, Sarmiento E, Chean C, Perez JL, Marin I, Rodriguez-Molina JJ, Gil J,
Fernandez-Cruz E: Humoral and cellular monitoring to predict the development of infection in Crohn’s
disease patients beginning treatment with infliximab. Ann N Y Acad Sci 2007;1107:346-355.
10. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts
PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ: Natalizumab for the
treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-1683.
11. Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R,
Hilton D, Hanauer SB: Safety and tolerability of concurrent natalizumab treatment for patients with
Crohn’s disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007;13:2-11.
Gyógyszerek, therápia 515
12. MacDonald JK, McDonald JW: Natalizumab for induction of remission in Crohn’s disease. Cochrane
Database Syst Rev 2007:CD006097.
13. Traynor K: FDA advisers endorse natalizumab for Crohn’s disease. Am J Health Syst Pharm
2007;64:1886, 1888, 1890.
14. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S:
Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357:228-238.
15. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R,
Sandborn WJ: Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007;
357:239-250.
16. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T:
Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor
necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-1332.
17. Kanai T, Makita S, Kawamura T, Nemoto Y, Kubota D, Nagayama K, Totsuka T, Watanabe M: Extra
corporeal elimination of TNF-alpha-producing CD14(dull)CD16(+) monocytes in leukocytapheresis
therapy for ulcerative colitis. Inflamm Bowel Dis 2007;13:284-290.
18. Ljung T, Thomsen OO, Vatn M, Karlen P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O,
Lindgren S, Befrits R, Lofberg R: Granulocyte, monocyte/macrophage apheresis for inflammatory
bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-227.
19. Takemoto K, Kato J, Kuriyama M, Nawa T, Kurome M, Okada H, Sakaguchi K, Shiratori Y: Predictive
factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis
2007;39:422-429.
20. Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K: Factors affecting clinical and
endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007;39:626-633.
21. Panes J, Guilera M, Ginard D, Hinojosa J, Gonzalez-Carro P, Gonzalez-Lara V, Varea V, Domenech E,
Badia X: Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? Dig Liver Dis
2007;39:617-625.
